DLL3 and small cell lung carcinoma: The significant prevalence of DLL3 and ASCL1 expression in early-stage SCLC, as highlighted by Furuta et al. and corroborated by our findings, underscores their potential as therapeutic targets and prognostic biomarkers [15].